Alarmingly, the use of anxiolytic Lorazepam, which has off-target agonism of GPR68, but not alprazolam, which does not activate GPR68, has recently been associated with a 3.8-fold higher rate of pancreatic cancer progression and related death than in non-users [23]. This evidence concerns the gene GPR68 and pancreatic neoplasm.